Follow The Filings

XBIO Xenetic Biosciences

Xenetic Biosciences earnings company data as of 4:47 AM ET 10/24

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by XBIO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All XBIO insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 7.01,9.01
SCHEDULE 13G —
8-K 1.01,3.02,7.01,9.01
8-K 2.02,9.01
10-Q FORM 10-Q FOR JUN 2026
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q QUARTERLY REPORT FOR MARCH 2026
8-K 5.02,9.01
10-K/A FORM 10-K FOR DEC 2025 AMENDMENT 1
8-K 2.02,9.01
10-K FORM 10-K FOR DEC 2025
SCHEDULE 13G —
8-K 8.01
8-K 7.01,9.01
DEFA14A ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS
8-K 2.02,9.01
10-Q FORM 10-Q FOR SEP 2025
DEF 14A DEFINITIVE PROXY STATEMENT
DEFA14A DEFINITIVE ADDITIONAL MATERIALS
424B5 FORM 424B5
8-K 1.01,8.01,9.01
424B5 FORM 424B5
8-K 2.02,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.